猕猴预存巨细胞病毒免疫影响人巨细胞病毒疫苗反应
在恒河猴和食蟹猴中接种编码HCMV gB和五聚体复合物的mRNA/LNP疫苗,两物种预存HCMV gB IgG结合反应均高,但预存PC反应主要见于恒河猴。第二次接种后两物种PC和gB特异性血浆IgG均至少升高1个对数级,并产生高上皮细胞中和抗体但有限成纤维细胞中和抗体,提示预存种特异性CMV免疫影响疫苗免疫原性。
要点
- 恒河猴和食蟹猴预存HCMV gB IgG结合反应均高。
- 第二次mRNA疫苗接种后PC和gB特异性IgG至少升高1个对数级。
- 预存种特异性CMV抗体反应影响HCMV疫苗免疫原性。
核心结论
- 种特异性CMV变异株抗体反应贡献于非人灵长类模型对HCMV疫苗的抗体反应。
- 预存免疫在非人灵长类临床前模型中必须被考虑,并将影响血清阳性人类受种者HCMV疫苗的免疫原性。
研究设计与样本
- 研究为临床前非人灵长类模型免疫原性评估。
- 食蟹猴16只(CyCMV血清阳性)和恒河猴24只(RhCMV血清阳性)经肌肉接种编码HCMV gB和五聚体复合物(PC)的mRNA/LNP疫苗。
主要发现
- 两物种预存HCMV gB IgG结合反应均高,但预存PC结合反应主要见于恒河猴。
- 第二次HCMV mRNA疫苗接种后两物种PC和gB特异性血浆IgG水平均至少升高1个对数级。
- 第二次接种后4周两物种均产生高上皮细胞中和抗体反应,但成纤维细胞中和抗体有限。
- 第二次接种后两物种均产生针对细胞相关gB(已确定的免疫保护相关物)的IgG结合反应。
- 恒河猴中疫苗接种前后gB特异性结合反应呈中度强直接相关。
临床怎么用
- 在非人灵长类临床前模型中评估HCMV疫苗免疫原性时需考虑种特异性CMV预存免疫的影响。
- 血清阳性人类受种者的预存CMV免疫可能影响HCMV疫苗免疫原性,疫苗设计或评价时应予以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of a human cytomegalovirus (HCMV) vaccine is a Tier 1 priority by the National Institutes of Medicine, as HCMV is the most common congenital infection globally and most frequent infectious complication in transplant patients. Relevant preclinical non-human primate models used for testing HCMV vaccine immunogenicity are rhesus and cynomolgous monkeys. However, a complication in using these models is that species-specific CMV variants are endemic in non-human primate breeding colonies. We hypothesize that natural immunity to species-specific CMV in rhesus and cynomolgous monkeys impacts HCMV vaccine immunogenicity and may interfere with our ability to fully interpret vaccine immunogenicity. A modified mRNA vaccine encoding HCMV glycoprotein (gB) and the pentameric complex (PC) packaged in lipid nanoparticles (LNP) was delivered intramuscularly to groups of cynomolgous (n = 16, CyCMV-seropositive) and rhesus macaques (n = 24, RhCMV-seropositive). High pre-vaccination IgG binding responses to HCMV gB were present in both species, but pre-vaccination binding responses to PC were mostly present in rhesus macaques. Yet, at least a log increase in both PC and gB-specific plasma IgG levels was detected post-second HCMV mRNA vaccination in both species. Both species responded with high epithelial cell neutralizing antibody responses at 4 weeks post second HCMV mRNA vaccination, but limited fibroblast neutralizing antibodies. HCMV gB + PC mRNA/LNP vaccine also elicited IgG binding responses to cell-associated gB, an identified immune correlate of protection, in both species after the second vaccination, and there was a moderately strong direct correlation between this pre- and post-vaccination response in rhesus macaques. Based on the correlation between pre-existing and post-vaccine gB-specific binding responses in rhesus macaques, we conclude that species-specific CMV variant-specific antibody responses contribute to antibody responses to HCMV vaccination in primate models, indicating that pre-existing immunity must be taken into account in non-human primate preclinical models and will impact immunogenicity of HCMV vaccines seropositive human vaccinees.
引用
- Webster H, Valencia S, Kumar A, et al. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. Vaccine. 2021. PMID: 34393017. doi:10.1016/j.vaccine.2021.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。